Research interests
Cancer metabolism and BCAT1-regulated cancer cell proliferation[6]
Through 2019
Journey
Education, training and research through time.
Undergraduate
Duke University
Medical school
Duke University School of Medicine
Residency
Columbia University Irving Medical Center and NewYork-Presbyterian Hospital
Fellowship
University of Pennsylvania
- Graduated in 2019; start date unknownUndergraduateDurham, North Carolina
Biology undergraduate education[6][8]
Duke's commencement program and Biology distinction booklet place Noteware in the 2019 graduating cohort and identify her Biology work. Neither source states when she began undergraduate study.
- Completed 2019·Completed undergraduate study[8]
- 2020
1 attributed work
- Completed May 14, 2023; start date unknownMedical schoolDurham, North Carolina
Doctor of Medicine[3][5]
Duke University School of Medicine
Duke's commencement program lists Noteware for the Doctor of Medicine on May 14, 2023. Penn independently names Duke as her medical school.
- May 14, 2023·Completed Doctor of Medicine[5]
- 2023
1 attributed work
- Brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced HER2 + breast cancer.
Breast cancer research and treatment · First author
- Brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced HER2 + breast cancer.
- 2024
1 attributed work
- Evolution of Initial Treatment for Desmoid Tumors.
Annals of surgical oncology
- Evolution of Initial Treatment for Desmoid Tumors.
- Graduated in 2026; start date unknownResidencyNew York, New York
Internal Medicine Residency[3][7]
Columbia University Irving Medical Center and NewYork-Presbyterian Hospital
Columbia lists Noteware among its 2026 residency graduates and names Penn cardiology as her destination. Penn independently names the Columbia and NewYork-Presbyterian residency.
- Completed 2026·Completed Internal Medicine Residency[7]
- Observed on current roster, Sep 4, 2026
- 2026
2 attributed works
- Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer.
NPJ precision oncology
- Heart Transplantation and Cancer Risk in a BRCA1 Breast Cancer Survivor.
JACC. Case reports · First author
- Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer.
Works appear by publication year. Their position does not establish where or when the underlying research was performed.
Education and training
Degrees, training periods and the milestones within them.
- Graduated in 2019; start date unknownUndergraduateDurham, North Carolina
Biology undergraduate education[6][8]
Duke's commencement program and Biology distinction booklet place Noteware in the 2019 graduating cohort and identify her Biology work. Neither source states when she began undergraduate study.
- Completed 2019·Completed undergraduate study[8]
- Completed May 14, 2023; start date unknownMedical schoolDurham, North Carolina
Doctor of Medicine[3][5]
Duke University School of Medicine
Duke's commencement program lists Noteware for the Doctor of Medicine on May 14, 2023. Penn independently names Duke as her medical school.
- May 14, 2023·Completed Doctor of Medicine[5]
- Graduated in 2026; start date unknownResidencyNew York, New York
Internal Medicine Residency[3][7]
Columbia University Irving Medical Center and NewYork-Presbyterian Hospital
Columbia lists Noteware among its 2026 residency graduates and names Penn cardiology as her destination. Penn independently names the Columbia and NewYork-Presbyterian residency.
- Completed 2026·Completed Internal Medicine Residency[7]
- Observed on current roster, Sep 4, 2026
Research
Publications
5 attributed works · 2 first author. Counts reflect resolved authorship and may be incomplete.
- 2026Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer.NPJ precision oncologyPMID 41826432
- 2026Heart Transplantation and Cancer Risk in a BRCA1 Breast Cancer Survivor.JACC. Case reportsfirst authorPMID 41563221
- 2024Evolution of Initial Treatment for Desmoid Tumors.Annals of surgical oncologyPMID 39133446
- 2023Brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced HER2 + breast cancer.Breast cancer research and treatmentfirst authorPMID 36403183
- 2020NRF2 activation promotes the recurrence of dormant tumour cells through regulation of redox and nucleotide metabolism.Nature metabolismPMID 32691018
Sources
Sources are listed once and connected to each accepted claim they support. Excerpts preserve the source language used in the review.
- [1]PubMed records
5 source claims · Reviewed Sep 5, 2026
Attributed work: Brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced HER2 + breast cancer. | DOI 10.1007/s10549-022-06799-7 | PMID 36403183
January 2023
Brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced HER2 + breast cancer.
Attributed work: Evolution of Initial Treatment for Desmoid Tumors. | DOI 10.1245/s10434-024-15938-x | PMID 39133446
November 2024
Evolution of Initial Treatment for Desmoid Tumors.
Attributed work: Heart Transplantation and Cancer Risk in a BRCA1 Breast Cancer Survivor. | DOI 10.1016/j.jaccas.2025.106608 | PMID 41563221
Feb 25, 2026
Heart Transplantation and Cancer Risk in a BRCA1 Breast Cancer Survivor.
Attributed work: NRF2 activation promotes the recurrence of dormant tumour cells through regulation of redox and nucleotide metabolism. | DOI 10.1038/s42255-020-0191-z | PMID 32691018
April 2020
NRF2 activation promotes the recurrence of dormant tumour cells through regulation of redox and nucleotide metabolism.
Attributed work: Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer. | DOI 10.1038/s41698-026-01365-6 | PMID 41826432
Mar 13, 2026
Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer.
- [2]Stead Scholar Noteware Highlights Need in HER2-Positive Breast Cancer Research
1 source claim · Reviewed Sep 5, 2026
Biographical context: Eugene A. Stead Student Research Scholar studying brain metastases in HER2-positive breast cancer with Sarah Sammons
2022
Supported by funding from the Duke Department of Medicine’s Eugene A. Stead Student Research Scholarship, fourth year medical student and internal medicine resident hopeful Laura Noteware is working to change that.
- [3]Reviewed current trainee roster
1 source claim · 3 journey details · Reviewed Sep 5, 2026
Doctor of Medicine: Completed May 14, 2023; start date unknown. Duke's commencement program lists Noteware for the Doctor of Medicine on May 14, 2023. Penn independently names Duke as her medical school.
Internal Medicine Residency: Graduated in 2026; start date unknown. Columbia lists Noteware among its 2026 residency graduates and names Penn cardiology as her destination. Penn independently names the Columbia and NewYork-Presbyterian residency.
First-year Cardiovascular Disease Fellow: Observed on current roster, Sep 4, 2026. Columbia names Penn cardiology as Noteware's destination, and Penn's roster places her among first-year cardiovascular disease fellows. The roster observation does not establish the full fellowship interval.
Fellowship: Cardiovascular Disease Fellowship, University of Pennsylvania
1st year fellows | Laura Noteware, MD | Medical School: Duke University School of Medicine | Residency Program: Residency Program at Columbia University Irving Medical Center and New York-Presbyterian Hospital Columbia
- [4]Original Duke composite bitmap with Laura C. Noteware as labelled center subject
1 source claim · Reviewed Sep 5, 2026
Official headshot: Portrait
The retained Duke article identifies Laura Noteware as its subject; the original bitmap's center coat visibly reads 'Laura C. Noteware'. The reviewed pixel region isolates that labelled center subject.
- [5]Duke University 2023 Commencement Program
1 source claim · 3 journey details · Reviewed Sep 5, 2026
Doctor of Medicine: Completed May 14, 2023; start date unknown. Duke's commencement program lists Noteware for the Doctor of Medicine on May 14, 2023. Penn independently names Duke as her medical school.
Completed Doctor of Medicine: May 14, 2023
Noteware's ORCID record has no education or employment entries. Duke and Columbia establish completion points for undergraduate study, medical school, and residency, but not their start dates.
Medical school: Duke University School of Medicine (MD)
Through May 14, 2023
SCHOOL OF MEDICINE | DOCTOR OF MEDICINE | May 14, 2023 | Laura Noteware
- [6]Duke Biology Graduation with Distinction 2019
2 source claims · 1 journey details · Reviewed Sep 5, 2026
Biology undergraduate education: Graduated in 2019; start date unknown. Duke's commencement program and Biology distinction booklet place Noteware in the 2019 graduating cohort and identify her Biology work. Neither source states when she began undergraduate study.
Research interests: Cancer metabolism and BCAT1-regulated cancer cell proliferation
Through 2019
Laura Noteware, Characterization of BCAT1 regulated cancer cell proliferation and senescence
Undergraduate education: Duke University; Biology
Through 2019
Laura Noteware, Characterization of BCAT1 regulated cancer metabolism, (Dr. James Alvarez, Department of Pharmacology and Cancer Biology)
- [7]Recent graduates | Columbia Internal Medicine Residency
1 source claim · 4 journey details · Reviewed Sep 5, 2026
Internal Medicine Residency: Graduated in 2026; start date unknown. Columbia lists Noteware among its 2026 residency graduates and names Penn cardiology as her destination. Penn independently names the Columbia and NewYork-Presbyterian residency.
Completed Internal Medicine Residency: 2026
First-year Cardiovascular Disease Fellow: Observed on current roster, Sep 4, 2026. Columbia names Penn cardiology as Noteware's destination, and Penn's roster places her among first-year cardiovascular disease fellows. The roster observation does not establish the full fellowship interval.
Noteware's ORCID record has no education or employment entries. Duke and Columbia establish completion points for undergraduate study, medical school, and residency, but not their start dates.
Residency: Internal Medicine Residency, Columbia University Irving Medical Center / NewYork-Presbyterian Columbia
Through 2026
2026 Graduates | Laura Noteware: Cardiology Fellowship at the University of Pennsylvania
- [8]Duke University 2019 Commencement Program
0 source claims · 3 journey details
Biology undergraduate education: Graduated in 2019; start date unknown. Duke's commencement program and Biology distinction booklet place Noteware in the 2019 graduating cohort and identify her Biology work. Neither source states when she began undergraduate study.
Completed undergraduate study: 2019
Noteware's ORCID record has no education or employment entries. Duke and Columbia establish completion points for undergraduate study, medical school, and residency, but not their start dates.
